With increasing number of biosimilars deemed fit for treatments of various diseases, doctors may have some relief from treating previously hard-to-manage disorders. The United States Food and Drugs Administration (USFDA ) has recently approved first biosimilar monoclonal antibody (mAb) therapy and only a second biosimilar which has been deemed suitabl for various diseases such as Crohn’s disease, Ulcerative colitis, and most importantly rheumatoid arthritis. In the last decade, the focus in the drug development has been tilted towards biosimilars from conventional chemical compounds.
Biosimilars are the biopharmaceutical drugs that are highly similar to previously accepted biological products for the treatment. The Indian government, in the last two years have devised a comprehensive policy to encourage research and development of biosimilars. Due to this step, India is one of only few…
